Abstract
There were studied effects of phosphodiesterase inhibitor Sildenafil on clinical and functional status in young patient with severe primary pulmonary hypertension. Sildenafil was applicated in dose of 50-100 mg daily for 12 weeks, clinical and functional status were estimated initial and after every month of treatment. The retrospective analysis do not detected any positive dynamics in all estimated parameters, this phenomena may be explained by individual patient refractivity on this group of medicine.
Highlights
Sildenafil was applicated in dose
The retrospective analysis do not detected any positive dynamics in all estimated parameters
this phenomena may be explained by individual patient refractivity on this group
Summary
Sildenafil a fost primul inhibitor selectiv al fosfodiesterazei (PDE) - GMPc tip 5, care a dovedit eficacitatea sa la pacienţii cu clasa funcţională II-III a hipertensiunii arteriale pulmonare primare (idiopatice) şi hipertensiunii arteriale pulmonare cauzate de maladiile a ţesutului conjuctiv. Sildenafil a fost administrat pacientei de 21 ani cu HPI în doza 50-100 mg/zi în perioada de 4 luni. Starea clinică şi funcţională a pacientei a fost estimată iniţial şi după fiecare lună de tratament.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
